<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03400709</url>
  </required_header>
  <id_info>
    <org_study_id>123606</org_study_id>
    <nct_id>NCT03400709</nct_id>
  </id_info>
  <brief_title>Protective Role of N-acetylcisteine From Cisplatin-induced Ototoxicity in Patients With Head and Neck Cancer</brief_title>
  <official_title>Protective Role of N-acetylcisteine From Cisplatin-induced Ototoxicity in Patients With Head and Neck Cancer. A Randomized, Placebo Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital San Juan de Dios, Santiago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital San Juan de Dios, Santiago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Introduction. Cisplatin-induced ototoxicity is a very frequent event and its consequences can
      cause a lot of deterioration in patients. Early diagnosis is essential because it would allow
      the appropriate implementation of strategies to reduce its effect. Among these
      N-acetylcysteine, an antioxidant agent that has shown otoprotective effect. Study design.
      Randomized, parallel design and placebo controlled clinical trial. Methods. Patients with
      head and neck cancer who require treatment with cisplatin were enrolled in 2 branches: a
      control group that receives a placebo and experimental group that receives the drug.
      High-frequency audiometries (6 - 16 KHz) are performed before, during and after the treatment
      finalization.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2015</start_date>
  <completion_date type="Actual">November 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hearing threshold</measure>
    <time_frame>Baseline.</time_frame>
    <description>High frequencies pure tone average</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hearing threshold</measure>
    <time_frame>up to 4th week of chemoradiotherapy</time_frame>
    <description>High frequencies pure tone average</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hearing threshold</measure>
    <time_frame>through study completion, an average of 3 months</time_frame>
    <description>High frequencies pure tone average</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Cisplatin Adverse Reaction</condition>
  <condition>Hearing Loss Ototoxic</condition>
  <arm_group>
    <arm_group_label>N-acetylcisteine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N Acetylcysteine</intervention_name>
    <description>Oral administration of drug, before, during and after Chemoradiotherapy including Cisplatin.</description>
    <arm_group_label>N-acetylcisteine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Placebo treatment</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults Patients with Head and Neck Squamous Cell carcinoma requiring Chemoradiotherapy
             including Cisplatin.

        Exclusion Criteria:

          -  Conductive Hearing Loss

          -  SNHL with &gt;= 40db PTA
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Daniel Munoz</name>
      <address>
        <city>Santiago</city>
        <state>Metropolitana</state>
        <zip>7160166</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 27, 2017</study_first_submitted>
  <study_first_submitted_qc>January 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2018</study_first_posted>
  <last_update_submitted>January 14, 2018</last_update_submitted>
  <last_update_submitted_qc>January 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital San Juan de Dios, Santiago</investigator_affiliation>
    <investigator_full_name>Daniel Munoz MD, MSc.</investigator_full_name>
    <investigator_title>Otolaryngologist, Clinical Epidemiologist.</investigator_title>
  </responsible_party>
  <keyword>Cisplatin</keyword>
  <keyword>Ototoxicity</keyword>
  <keyword>N-acetylcisteine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Hearing Loss</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

